# Sensitivity, Specificity, and Accuracy of Ultrasound, Mammography, and 18F-FDG PET/CT in Diagnosing Breast Cancer Metastasis to Axillary Lymph Nodes: A Single-Center Experience

**Authors:** Gokmen Aktas, Hakan Buyukhatipoglu, Tulay Kus, Mehmet Emin Kalender, Hamit Yıldız, Talha Yıldız, Alper Sevinç, Seval Kul, Celaletdin Camci

PMC · DOI: 10.3390/medicina62020320 · 2026-02-04

## TL;DR

This study compares the effectiveness of ultrasound, mammography, and PET/CT in detecting breast cancer spread to lymph nodes, finding that ultrasound is less reliable for early-stage cancer.

## Contribution

The study provides a single-center comparison of diagnostic accuracy for axillary lymph node metastasis detection using three imaging modalities.

## Key findings

- Ultrasound had a sensitivity of 33.3% and high specificity of 97.5% for detecting lymph node metastasis.
- PET/CT showed the highest accuracy (82.5%) with 72.5% sensitivity and 100% specificity.
- Ultrasound false negatives were more common in early-stage (T1) and node-positive (N1) tumors.

## Abstract

Background and Objectives: Axillary lymph node (ALN) status is one of the most important prognostic factors in breast cancer. Numerous studies have evaluated less invasive methods for accurate staging. To investigate the diagnostic performance of ultrasound (US), mammography, and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting axillary lymph node metastasis in breast cancer patients. Materials and Methods: Axillary involvement detected by US, mammography, and 18F-FDG PET/CT was analyzed in patients who underwent axillary dissection. Preoperatively, 365, 318, and 85 of 557 patients were evaluated with US, mammography, and PET/CT, respectively. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of each imaging modality were calculated. Results: The sensitivity, specificity, PPV, NPV, and accuracy of US were 33.3%, 97.5%, 94.4%, 51.0%, and 57.8%, respectively. False-negative US findings were more frequent in T1 (84.6%) and N1 (76.3%) tumors (p < 0.001 for both). For mammography, these values were 12.9%, 97.74%, 88.89%, 44.67%, and 52.9%, while for 18F-FDG PET/CT they were 72.5%, 100%, 100%, 67.65%, and 82.5%, respectively. Conclusions: Ultrasound remains useful for evaluating axillary lymph node involvement in advanced breast cancer but is insufficient for early-stage disease.

## Linked entities

- **Chemicals:** 18F-FDG (PubChem CID 68614)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}
- **Diseases:** axillary lymph node (ALN) metastases (MESH:D008207), negative (MESH:D064726), Breast Cancer (MESH:D001943), invasive ductal carcinoma (MESH:D044584), ALN (MESH:D000072717), Metastasis (MESH:D009362), inflammatory carcinoma (MESH:D058922), breast metastases (MESH:D061325), stage IV disease (MESH:D007676), nodal (MESH:D013611), invasive lobular carcinoma (MESH:D018275), node (MESH:D012804), N1 disease (MESH:D004194), injury to (MESH:D014947), Tumor (MESH:D009369)
- **Chemicals:** 18F-FDG (MESH:D019788), Blood glucose (MESH:D001786)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12941819